Replimune Group (NASDAQ:REPL) Raised to Neutral at JPMorgan Chase & Co.

Replimune Group (NASDAQ:REPL) was upgraded by investment analysts at JPMorgan Chase & Co. from an “underweight” rating to a “neutral” rating in a research report issued to clients and investors on Friday, Marketbeat Ratings reports. The brokerage currently has a $8.00 price objective on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential downside of 7.48% from the company’s current price.

REPL has been the topic of several other reports. Jefferies Financial Group reaffirmed a “hold” rating and set a $2.00 target price (down from $13.00) on shares of Replimune Group in a research note on Monday, April 13th. Wall Street Zen raised shares of Replimune Group from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 23rd. Cantor Fitzgerald downgraded shares of Replimune Group from an “overweight” rating to a “hold” rating in a research report on Monday, April 13th. Weiss Ratings raised shares of Replimune Group from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 8th. Finally, Leerink Partners reiterated a “market perform” rating and set a $2.00 price target (down from $11.00) on shares of Replimune Group in a research note on Monday, April 13th. Seven analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average target price of $4.38.

Replimune Group Price Performance

Shares of NASDAQ REPL traded up $3.97 during trading on Friday, hitting $8.65. The company had a trading volume of 44,434,599 shares, compared to its average volume of 4,699,200. The firm has a market capitalization of $713.98 million, a price-to-earnings ratio of -2.52 and a beta of 0.12. The stock has a fifty day simple moving average of $4.84 and a two-hundred day simple moving average of $7.25. Replimune Group has a fifty-two week low of $1.50 and a fifty-two week high of $13.24. The company has a quick ratio of 5.60, a current ratio of 5.60 and a debt-to-equity ratio of 0.33.

Insider Buying and Selling

In other Replimune Group news, insider Christopher Sarchi sold 6,500 shares of the company’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $8.01, for a total value of $52,065.00. Following the transaction, the insider directly owned 151,588 shares in the company, valued at approximately $1,214,219.88. This represents a 4.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.20% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

Several hedge funds and other institutional investors have recently modified their holdings of REPL. RTW Investments LP lifted its holdings in Replimune Group by 11.6% in the fourth quarter. RTW Investments LP now owns 7,140,352 shares of the company’s stock worth $69,404,000 after purchasing an additional 744,620 shares during the period. Fcpm Iii Services B.V. raised its holdings in Replimune Group by 6.4% during the 3rd quarter. Fcpm Iii Services B.V. now owns 4,158,368 shares of the company’s stock worth $17,424,000 after buying an additional 248,672 shares during the period. State Street Corp increased its holdings in shares of Replimune Group by 26.3% in the 4th quarter. State Street Corp now owns 3,693,107 shares of the company’s stock valued at $35,897,000 after purchasing an additional 768,982 shares during the period. Vanguard Group Inc. grew its stake in shares of Replimune Group by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 3,479,395 shares of the company’s stock valued at $14,579,000 after buying an additional 9,707 shares in the last quarter. Finally, Braidwell LP grew its stake in shares of Replimune Group by 550.3% in the 3rd quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock valued at $11,523,000 after buying an additional 2,327,205 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.